CeriBell (NASDAQ:CBLL) CTO Raymond Woo Sells 1,966 Shares

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 1,966 shares of the firm’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $18.00, for a total transaction of $35,388.00. Following the transaction, the chief technology officer directly owned 195,682 shares of the company’s stock, valued at $3,522,276. The trade was a 0.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Raymond Woo also recently made the following trade(s):

• On Friday, May 1st, Raymond Woo sold 11,104 shares of CeriBell stock. The stock was sold at an average price of $20.44, for a total transaction of $226,965.76.
• On Wednesday, April 1st, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $18.56, for a total transaction of $206,238.72.
• On Monday, March 2nd, Raymond Woo sold 8,087 shares of CeriBell stock. The shares were sold at an average price of $18.25, for a total transaction of $147,587.75.

CeriBell Trading Up 0.2%

CBLL opened at $18.80 on Wednesday. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $24.33. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. The company has a market cap of $713.27 million, a P/E ratio of -11.53 and a beta of 0.99. The company has a fifty day moving average price of $19.09 and a two-hundred day moving average price of $19.24.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). The business had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. Analysts predict that CeriBell, Inc. will post -1.69 EPS for the current fiscal year.

Institutional Trading of CeriBell

Hedge funds and other institutional investors have recently modified their holdings of the business. CenterBook Partners LP raised its position in shares of CeriBell by 448.0% in the third quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock valued at $5,476,000 after purchasing an additional 389,584 shares during the period. JPMorgan Chase & Co. raised its position in shares of CeriBell by 8.2% in the third quarter. JPMorgan Chase & Co. now owns 411,180 shares of the company’s stock valued at $4,724,000 after purchasing an additional 31,177 shares during the period. GSA Capital Partners LLP bought a new stake in shares of CeriBell in the third quarter valued at approximately $158,000. TimesSquare Capital Management LLC raised its position in shares of CeriBell by 2.6% in the third quarter. TimesSquare Capital Management LLC now owns 817,645 shares of the company’s stock valued at $9,395,000 after purchasing an additional 20,700 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of CeriBell in the first quarter valued at approximately $341,000.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Weiss Ratings cut shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 12th. Canaccord Genuity Group cut their price target on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research report on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.